Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 7Glioma 5Glioblastoma 4Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Gliosarcoma 2Fallopian Tube Neoplasms 2Central Nervous System Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Astrocytoma 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Testicular Neoplasms 1Skin Neoplasms 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Metastatic Castration-resistant Prostate Cancer 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

enzalutamide 5olaparib 4Abiraterone Acetate 4radium Ra 223 dichloride 2poly ICLC 1fluciclovine F-18 1darolutamide 1bempegaldesleukin 1avelumab 1abiraterone 1Radiosurgery 1Prednisone 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Metastatic Castration-resistant Prostate Cancer × poly ICLC × Clear all
NCT03835533 2024-04-12

PORTER

Parker Institute for Cancer Immunotherapy

Phase 1 Completed
43 enrolled 19 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡